BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cevostamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cevostamab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05535244-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Cevostamab: Phase 1/2 readout est. (NCT05535244)
DESCRIPTION:Cevostamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation An
 tigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myelom
 a\nEstimated primary completion: 26 February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05535244
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801939-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cevostamab: Phase 2 readout est. (NCT05801939)
DESCRIPTION:Cevostamab\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab Fol
 lowing CAR T Cell Therapy for RRMM\nEstimated primary completion: May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cevostamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05801939
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05927571-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cevostamab: Phase 1 readout est. (NCT05927571)
DESCRIPTION:Cevostamab\, phase 1\, Multiple Myeloma.\nStudy: A Study Evalua
 ting the Safety\, Pharmacokinetics\, and Activity of the Combination of Ce
 vostamab and Elranatamab in Participants With Relapsed or Refractory Multi
 ple Myeloma (R/R MM)\nEstimated primary completion: 31 July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cevostamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05927571
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Cevostamab: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Cevostamab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Exa
 mine the Effects of Novel Therapy Linvoseltamab in Combination With Other 
 Cancer Treatments for Adult Participants With Multiple Myeloma That is Res
 istant to Current Standard of Care Treatments\nEstimated primary completio
 n: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cev
 ostamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05137054
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cevostamab: Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Cevostamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Safety and Efficacy of Multiple Treatments in Participants With
  Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934044-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Cevostamab: Phase 1 readout est. (NCT06934044)
DESCRIPTION:Cevostamab\, phase 1\, Multiple Myeloma.\nStudy: A Study Evalua
 ting the Pharmacokinetics\, Safety\, and Efficacy of Cevostamab in Chinese
  Participants With Relapsed or Refractory Multiple Myeloma\nEstimated prim
 ary completion: 15 November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cevostamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06934044
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555938-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cevostamab: Phase 3 readout est. (NCT07555938)
DESCRIPTION:Cevostamab\, phase 3\, Multiple Myeloma.\nStudy: Cevostamab in 
 Combination With Pomalidomide and Dexamethasone Versus Standard of Care in
  Participants With Previously Treated Multiple Myeloma\nEstimated primary 
 completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cevostamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07555938
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910568-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Cevostamab: Phase 1 readout est. (NCT04910568)
DESCRIPTION:Cevostamab\, phase 1\, Multiple Myeloma.\nStudy: A Study Evalua
 ting the Safety\, Pharmacokinetics\, and Activity of Cevostamab in Partici
 pants With Relapsed or Refractory Multiple Myeloma\nEstimated primary comp
 letion: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cevostamab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04910568
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Cevostamab: Phase 2 readout est. (NCT07825064)
DESCRIPTION:Cevostamab\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab in 
 Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR 
 T-Cell Therapy in Participants With Previously Treated Multiple Myeloma\nE
 stimated primary completion: 13 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629583-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20300329
DTEND;VALUE=DATE:20300330
SUMMARY:Cevostamab: Phase 1 readout est. (NCT07629583)
DESCRIPTION:Cevostamab\, phase 1\, Systemic Lupus Erythematosus.\nStudy: To
  Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Er
 ythematosus With or Without Active Lupus Nephritis\nEstimated primary comp
 letion: 29 March 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cevostamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07629583
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07342114-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20300617
DTEND;VALUE=DATE:20300618
SUMMARY:Cevostamab: Phase 1 readout est. (NCT07342114)
DESCRIPTION:Cevostamab\, phase 1\, Multiple Myeloma.\nStudy: A Clinical Stu
 dy to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7
 875913 With Cevostamab in Participants With Relapsed/Refractory Multiple M
 yeloma\nEstimated primary completion: 17 June 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07342114
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831122-3151@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20330131
DTEND;VALUE=DATE:20330201
SUMMARY:Cevostamab: Phase 1 readout est. (NCT07831122)
DESCRIPTION:Cevostamab\, phase 1\, Multiple Myeloma.\nStudy: Study of Belan
 tamab Mafodotin\, Cevostamab\, Pomalidomide for RRMM Patients (MAPLE)\nEst
 imated primary completion: January 2033. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07831122
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
